[Federal Register: February 14, 2007 (Volume 72, Number 30)]
[Notices]
[Page 7104-7106]
[DOCID:fr14fe07-141]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-55254; File No. SR-Phlx-2006-88]

 Self-Regulatory Organizations; Philadelphia Stock Exchange,
Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule
Change Relating to Rule 712, Independent Audit

February 8, 2007.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934

(``Act'') \1\, and Rule 19b-4 thereunder,\2\ notice is hereby given
that on December 21, 2006, the Philadelphia Stock Exchange, Inc.
(``Phlx'' or ``Exchange'') filed with the Securities and Exchange
Commission (``SEC'' or ``Commission'') the proposed rule change as
described in Items I, II, and III, below, which Items have been
prepared by the Phlx. The Exchange has designated this proposal as one
establishing or changing a due, fee, or other charge imposed by Phlx
under Section 19(b)(3)(A)(ii) \3\ of the Act and Rule 19b-4(f)(2) \4\
thereunder, which renders the proposal effective upon filing with the
Commission. The Commission is publishing this notice to solicit
comments on the proposed rule change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ 15 U.S.C. 78s(b)(3)(A)(ii).
    \4\ 17 CFR 240.19b-4(f)(2).
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Phlx, pursuant to Section 19(b)(1) of the Act \5\ and Rule 19b-
4 thereunder,\6\ proposes to amend Phlx Rule 712, Independent Audit, to
clarify that in certain circumstances a member organization may request
an extension of time to file its annual audit from the Exchange in
writing prior to the due date of the annual audit, and to provide for
the imposition of a fee to be assessed for the late filing of an annual
audited financial statement (``annual audit'').
---------------------------------------------------------------------------

    \5\ 15 U.S.C. 78s(b)(1).
    \6\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

    The proposed new language is set forth below, with new text
italicized:
Rules of the Board of Governors
* * * * *
Independent Audit
    Rule 712. Each member organization doing any business with the
public shall at least once each calendar year cause to be made an audit
of its affairs, conducted in accordance with applicable audit
requirements of the Securities and Exchange Commission and such other
requirements as deemed appropriate by the Exchange, by independent
public accountants and shall have such accountants prepare an answer to
the financial questionnaire of the Exchange based upon such audit.
    Pursuant to Rule 17a-5(d), promulgated under the Exchange Act, all
broker-dealers are required to file annually audited financial
statements (``Annual Audits'') with their Designated Examining
Authority and the SEC, no more than 60 days after the date of the year
end financial statements. A member organization unable to meet the
filing deadline for its Annual Audit as a result of exceptional
circumstances may request an extension of time, in writing, prior to
the filing due date. Annual Audits not received by the Exchange by the
due date, or revised due date if an extension has been granted, will be
subject to a late fee as set forth below for each week or any part
thereof that the Annual Audit has not been filed, as calculated based
on the due date or revised due date for filing the Annual Audit.
(Implemented on a running three-year basis.)
    (i) $100 per week for the first late filing in a three-year period.
    (ii) $300 per week for the second late filing in a three-year
period.
    (iii) $1,000 per week for the third late filing in a three-year
period.
* * * * *

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Phlx included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Phlx has substantially prepared summaries, set forth
in sections A, B, and C below, of the most significant aspects of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    Currently, Rule 712 sets forth the provisions governing the
requirements for an annual audit to be conducted in accordance with
audit requirements as set forth by the Securities and Exchange
Commission and other requirements as deemed appropriate by the
Exchange. The proposed amendment is designed to clarify that, if a
member organization is unable to meet the filing deadline for its
annual audit as a result of exceptional circumstances, the member
organization may request an extension of time to file its annual audit
in writing prior to the due date of the annual audit.\7\ In addition,
the proposed amendment is intended to encourage the prompt filing of
annual audits by those member organizations designated to the Exchange
for examining purposes through the assessment of a late filing fee.
Pursuant to the amended Rule, the Exchange may issue progressively
higher fees for all subsequent violations within the running three-year
time period.\8\
---------------------------------------------------------------------------

    \7\ Requests for extensions of time to file an annual audit
should be submitted to the Exchange.
    \8\ The Exchange may present repeated or aggravated failures to
file such annual audits on a timely basis to the Exchange's Business
Conduct Committee for disciplinary action under Exchange Rules.
---------------------------------------------------------------------------

2. Statutory Basis
    The Exchange believes that its proposal to amend its schedule of
fees is consistent with Section 6(b) of the Act \9\ in general, and
furthers the objectives of Section 6(b)(4) of the Act \10\ in
particular, in that it is an equitable allocation of reasonable fees
and other charges among Exchange members.
---------------------------------------------------------------------------

    \9\ 15 U.S.C. 78f(b).
    \10\ 15 U.S.C. 78f(b)(4).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition not necessary or appropriate in
furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    No written comments were either solicited or received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    The foregoing rule change has become effective pursuant to section
19(b)(3)(A)(ii) of the Act \11\ and paragraph (f)(2) of Rule 19b-4 \12\
thereunder. At any time within 60 days of the filing of the proposed
rule change, the Commission may summarily abrogate such rule change if
it appears to the Commission that such action is necessary or
appropriate in the public interest, for the protection of investors, or
otherwise in furtherance of the purposes of the Act.
---------------------------------------------------------------------------

    \11\ 15 U.S.C. 78s(b)(3)(A)(ii).
    \12\ 17 CFR 240.19b-4(f)(2).
---------------------------------------------------------------------------

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml.
); or     Send an e-mail to<EMAIL_ADDRESS>Please include

File Number SR-Phlx-2006-88 on the subject line.

Paper Comments

     Send paper comments in triplicate to Nancy M. Morris,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-Phlx-2006-88. This file
number should be included on the subject line if e-mail is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml
). Copies of the submission, all subsequent amendments, all

written statements with respect to the proposed rule change that are
filed with the Commission, and all written communications relating to
the proposed rule change between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for inspection and
copying in the Commission's Public Reference Room. Copies of the filing
also will be available for inspection and copying at the principal
office of the Phlx. All comments received will be posted without
change; the Commission does not edit personal identifying information
from submissions. You should submit only information that you wish to
make available publicly. All submissions should refer to File Number
SR-Phlx-2006-88 and should be submitted on or before March 7, 2007.
---------------------------------------------------------------------------

    \13\ 17 CFR 200.30-3(a)(12).

    For the Commission, by the Division of Market Regulation,
pursuant to delegated authority.\13\
Florence E. Harmon,
Deputy Secretary.
[FR Doc. E7-2549 Filed 2-13-07; 8:45 am]

BILLING CODE 8010-01-P


[Federal Register Volume 81, Number 135 (Thursday, July 14, 2016)]
[Rules and Regulations]
[Pages 45405-45407]
[FR Doc No: 2016-16639]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 25

[Docket No. FAA-2016-6136; Special Conditions No. 25-620-SC]

Special Conditions: American Airlines, Boeing 777-200 Series
Airplanes; Dynamic Test Requirements for Single-Occupant Oblique (Side-
Facing) Seats Equipped With Inflatable Lapbelts

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final special conditions; request for comments.

-----------------------------------------------------------------------

SUMMARY: These special conditions are issued for the Boeing 777-200
series airplane. This airplane, as modified by American Airlines, will
have novel or unusual design features when compared to the state of
technology envisioned in the airworthiness standards for transport-
category airplanes. These airplanes will include single-occupant
oblique seats with inflatable lapbelts requiring dynamic testing. The
applicable airworthiness regulations do not contain adequate or
appropriate safety standards for these design features. These special
conditions contain the additional safety standards that the
Administrator considers necessary to establish a level of safety
equivalent to that established by the existing airworthiness standards.

DATES: This action is effective on American Airlines on July 14, 2016.
We must receive your comments by August 29, 2016.

ADDRESSES: Send comments identified by docket number FAA-2016-6136
using any of the following methods:
     Federal eRegulations Portal: Go to http://www.regulations.gov/and follow the online instructions for sending your
comments electronically.
     Mail: Send comments to Docket Operations, M-30, U.S.
Department of Transportation (DOT), 1200 New Jersey Avenue SE., Room
W12-140, West Building Ground Floor, Washington, DC 20590-0001.
     Hand Delivery or Courier: Take comments to Docket
Operations in Room W12-140 of the West Building Ground Floor at 1200
New Jersey Avenue SE., Washington, DC, between 9 a.m. and 5 p.m.,
Monday through Friday, except Federal holidays.
     Fax: Fax comments to Docket Operations at<PHONE_NUMBER>.
    Privacy: The FAA will post all comments it receives, without
change, to http://www.regulations.gov/, including any personal
information the commenter provides. Using the search function of the
docket Web site, anyone can find and read the electronic form of all
comments received into any FAA docket, including the name of the
individual sending the comment (or signing the comment for an
association, business, labor union, etc.). DOT's complete Privacy Act
Statement can be found in the Federal Register published on April 11,
2000 (65 FR 19477-19478), as well as at http://DocketsInfo.dot.gov/ gov/.
    Docket: Background documents or comments received may be read at
http://www.regulations.gov/ at any time. Follow the online instructions
for accessing the docket or go to Docket Operations in Room W12-140 of
the West Building Ground Floor at 1200 New Jersey Avenue SE.,
Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday,
except Federal holidays.

FOR FURTHER INFORMATION CONTACT: John Shelden, FAA, Airframe and Cabin
Safety Branch, ANM-115, Transport Airplane Directorate, Aircraft
Certification Service, 1601 Lind Avenue SW., Renton, Washington 98057-
3356; telephone<PHONE_NUMBER>; facsimile<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: The FAA has determined that notice of, and
opportunity for prior public comment on, these special conditions is
impracticable because these procedures would significantly delay
issuance of the design approval and thus delivery of the affected
airplanes.
    In addition, the substance of these special conditions has been
subject to the public comment process in several prior instances with
no substantive comments received. The FAA therefore finds that good
cause exists for making these special conditions effective upon
publication in the Federal Register.

Comments Invited

    We invite interested people to take part in this rulemaking by
sending written comments, data, or views. The most helpful comments
reference a specific portion of the special conditions, explain the
reason for any recommended change, and include supporting data.
    We will consider all comments we receive by the closing date for
comments. We may change these special conditions based on the comments
we receive.

Background

    On November 3, 2015, American Airlines applied for a supplemental
type certificate for installation of TSO-C39c-approved B/E Aerospace
Super Diamond model oblique business-class passenger seats in Boeing
Model 777-200 series airplanes. The Model 777-200 airplane, approved
under type certificate no. T00001SE, is a transport-category, twin-
engine jet airplane with a maximum capacity of 440 passengers and a
maximum takeoff weight of 535,000 lbs.

Type Certification Basis

    Under the provisions of Title 14, Code of Federal Regulations (14
CFR) 21.101, American Airlines must show that the Boeing Model 777-200
series airplane, as changed, continues to meet the applicable
provisions of the regulations listed in type certificate no. T00001SE,
or the applicable regulations in effect on

the date of application for the change, except for earlier amendments
as agreed upon by the FAA.
    In addition, the certification basis includes certain special
conditions, exemptions, or later amended sections of the applicable
part that are not relevant to these special conditions.
    If the Administrator finds that the applicable airworthiness
regulations (i.e., 14 CFR part 25) do not contain adequate or
appropriate safety standards for the Boeing Model 777-200 series
airplane because of a novel or unusual design feature, special
conditions are prescribed under the provisions of Sec.  21.16.
    Special conditions are initially applicable to the model for which
they are issued. Should the applicant apply for a supplemental type
certificate to modify any other model included on the same type
certificate to incorporate the same novel or unusual design feature,
these special conditions would also apply to the other model under
Sec.  21.101.
    In addition to the applicable airworthiness regulations and special
conditions, the Boeing Model 777-200 series airplane must comply with
the fuel-vent and exhaust-emission requirements of 14 CFR part 34, and
the noise-certification requirements of 14 CFR part 36.
    The FAA issues special conditions, as defined in 14 CFR 11.19, in
accordance with Sec.  11.38, and they become part of the type
certification basis under Sec.  21.101.

Novel or Unusual Design Features

    The Boeing Model 777-200 series airplane will incorporate the
following novel or unusual design features: Single-occupant oblique
(side-facing) seats with inflatable lapbelts.

Discussion

    Amendment 25-15 to part 25, dated October 24, 1967, introduced the
subject of side-facing seats, and a requirement that each occupant in a
side-facing seat must be protected from head injury by a safety belt
and a cushioned rest that will support the arms, shoulders, head, and
spine.
    Subsequently, Amendment 25-20, dated April 23, 1969, clarified the
definition of side-facing seats to require that each occupant of a seat
that is positioned at more than an 18-degree angle to the vertical
plane containing the airplane centerline must be protected from head
injury by a safety belt and an energy-absorbing rest that supports the
arms, shoulders, head, and spine; or by a safety belt and shoulder
harness that prevents the head from contacting injurious objects. The
FAA concluded that a maximum 18-degree angle would provide an adequate
level of safety based on tests that were performed at the time, and
thus adopted that standard.
    Amendment 25-64, dated June 16, 1988, revised the emergency-landing
conditions that must be considered in the design of the airplane. It
revised the static-load conditions in Sec.  25.561 and added a new
Sec.  25.562, requiring dynamic testing for all seats approved for
occupancy during takeoff and landing. The intent was to provide an
improved level of safety for occupants on transport-category airplanes.
Because most seating on transport-category airplanes is forward-facing,
the pass/fail criteria developed in Amendment 25-64 focused primarily
on forward-facing seats. Therefore, the testing specified in the rule
did not provide a complete measure of occupant injury in seats that are
not forward-facing. However, Sec.  25.785 does require that occupants
of all seats that are occupied during taxi, takeoff, and landing not
suffer serious injury as a result of the inertia forces specified in
Sec. Sec.  25.561 and 25.562.
    To address recent research findings and accommodate commercial
demand, the FAA developed a methodology to address all fully side-
facing seats (i.e., seats oriented in the airplane with the occupant
facing 90 degrees to the direction of airplane travel) and has
documented those requirements in a set of proposed new special
conditions. The FAA issued policy statement PS-ANM-25-03-R1 on November
12, 2012, titled, ``Technical Criteria for Approving Side-Facing
Seats,'' which conveys the injury criteria to be used in the special
conditions. Some of those criteria are applicable to oblique seats but
others are not, because the motion of an occupant in an oblique seat is
different from the motion of an occupant in a fully side-facing seat
during emergency landing conditions.
    For shallower installation angles, the FAA has granted equivalent
level of safety (ELOS) findings for oblique-seat installations on the
premise that an occupant's kinematics in an oblique seat during a
forward impact would result in the body aligning with the impact
direction. We predicted that the occupant response would be similar to
an occupant of a forward-facing seat, and would produce a level of
safety equivalent to that of a forward-facing seat. These ELOS findings
were subject to many conditions that reflected the injury-evaluation
criteria and mitigation strategies available at the time of issuance of
the ELOS. However, review of dynamic test results for many of these
oblique seat installations raised concerns that the premise was not
correct. Potential injury mechanisms exist that are unique to oblique
seats and are not mitigated by the ELOS self-alignment approach even if
the occupant appears to respond similarly to a forward-facing seat.
    These seats will be installed at a maximum angle of 30 degrees to
the aircraft centerline and will include an inflatable lapbelt
restraint system for occupant restraint and injury protection.
    The airbag in the inflatable lapbelt is designed to limit occupant
forward excursion in the event of an emergency landing condition. This
reduces the potential for head injury, thereby reducing the Head Injury
Criteria (HIC) measurement. The use of an inflatable airbag in this
fashion is novel for commercial aviation.
    These special conditions contain the additional safety standards
that the Administrator considers necessary to establish a level of
safety equivalent to that established by the existing airworthiness
standards.

Applicability

    As discussed above, these special conditions are applicable to the
Boeing Model 777-200 series airplane. Should American Airlines apply at
a later date for a supplemental type certificate to modify any other
model included on type certificate no. T00001SE, to incorporate the
same novel or unusual design feature, these special conditions would
apply to that model as well.

Conclusion

    This action affects only certain novel or unusual design features
on one model series of airplane. It is not a rule of general
applicability and affects only the applicant who applied to the FAA for
approval of these features on the airplane.
    The substance of these special conditions has been subject to the
public-comment process with no substantive comments received. It is
unlikely that prior public comment would result in a significant change
from the substance contained herein. Therefore, because a delay would
significantly affect the certification of the airplane, the FAA has
determined that prior public notice and comment are unnecessary and
impracticable, and good cause exists for adopting these special
conditions upon publication in the Federal Register. The FAA is
requesting comments to allow interested persons to submit views that
may not have been submitted in response to the prior opportunities for
comment described above.

List of Subjects in 14 CFR Part 25

    Aircraft, Aviation safety, Reporting and recordkeeping
requirements.

    The authority citation for these special conditions is as follows:

    Authority: 49 U.S.C. 106(g), 40113, 44701, 44702, 44704.

The Special Conditions

    Accordingly, pursuant to the authority delegated to me by the
Administrator, the following special conditions are issued as part of
the type certification basis for Boeing Model 777-200 series airplanes
modified by American Airlines.
    In addition to the requirements of Sec.  25.562:

1. Head-Injury Criteria

    Compliance with Sec.  25.562(c)(5) is required, except that, if the
anthropomorphic test device (ATD) has no apparent contact with the
seat/structure but has contact with an airbag, a HIC unlimited score in
excess of 1000 is acceptable, provided the HIC15 score (calculated in
accordance with 49 CFR 571.208) for that contact is less than 700.

2. Body-to-Wall/Furnishing Contact

    If a seat is installed aft of structure (e.g. interior wall or
furnishings) that does not provide a homogenous contact surface for the
expected range of occupants and yaw angles, then additional analysis
and/or tests may be required to demonstrate that the injury criteria
are met for the area which an occupant could contact. For example, if
an airbag device is present, different yaw angles could result in
different airbag-device performance, and additional analysis or
separate tests may be necessary to evaluate performance.

3. Neck Injury Criteria

    The seating system must protect the occupant from experiencing
serious neck injury. If an airbag device is present, the assessment of
neck injury must be conducted with the airbag device activated, unless
there is reason to also consider that the neck-injury potential would
be higher for impacts below the airbag-device deployment threshold.
    a. The Nij (calculated in accordance with 49 CFR
571.208) must be below 1.0, where Nij =Fz/
Fzc + My/Myc, and Nij
critical values are:

i. Fzc = 1530 lb for tension
ii. Fzc = 1385 lb for compression
iii. Myc = 229 lb-ft in flexion
iv. Myc = 100 lb-ft in extension

    b. In addition, peak upper-neck Fz must be below 937 lb
in tension and 899 lb in compression.
    c. Rotation of the head about its vertical axis, relative to the
torso, is limited to 105 degrees in either direction from forward-
facing.
    d. The neck must not impact any surface that would produce
concentrated loading on the neck.

4. Spine and Torso Injury Criteria

    a. The lumbar spine tension (Fz) cannot exceed 1200 lb.
    b. Significant concentrated loading on the occupant's spine, in the
area between the pelvis and shoulders during impact, including rebound,
is not acceptable. During this type of contact, the interval for any
rearward (X direction) acceleration exceeding 20g must be less than 3
milliseconds as measured by the thoracic instrumentation specified in
49 CFR part 572, subpart E, filtered in accordance with SAE
International (SAE) Recommended Practice J211/1, ``Instrumentation for
Impact Test--Part 1--Electronic Instrumentation.''
    c. The occupant must not interact with the armrest or other seat
components in any manner significantly different than would be expected
for a forward-facing seat installation.

5. Pelvis Criteria

    Any part of the load-bearing portion of the bottom of the ATD
pelvis must not translate beyond the edges of the seat bottom seat-
cushion supporting structure.

6. Femur Criteria

    Axial rotation of the upper leg (about the z-axis of the femur per
SAE Recommended Practice J211/1) must be limited to 35 degrees from the
nominal seated position. Evaluation during rebound does not need to be
considered.

7. ATD and Test Conditions

    Longitudinal tests conducted to measure the injury criteria above
must be performed with the FAA Hybrid III ATD, as described in SAE
1999-01-1609, ``A Lumbar Spine Modification to the Hybrid III ATD for
Aircraft Seat Tests,'' V. Gowdy, et al. (1999). The tests must be
conducted with an undeformed floor, at the most-critical yaw cases for
injury, and with all lateral structural supports (e.g., armrests or
walls) installed.
    Note: In addition to these special conditions, the inflatable
lapbelts must meet the criteria of special conditions no. 25-187A-SC,
titled, ``Boeing Model 777 Series Airplanes; Seats with Inflatable
Lapbelts.''

    Issued in Renton, Washington, on July 7, 2016.
Michael Kaszycki,
Assistant Manager, Transport Airplane Directorate, Aircraft
Certification Service.
[FR Doc. 2016-16639 Filed 7-13-16; 8:45 am]
 BILLING CODE 4910-13-P


[Federal Register Volume 76, Number 240 (Wednesday, December 14, 2011)]
[Notices]
[Pages 77824-77825]
[FR Doc No: 2011-31987]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2005-0220; FRL-9326-5]

Dicofol; Cancellation Order for Certain Pesticide Registrations

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces EPA's order for the cancellations,
voluntarily requested by the registrants and accepted by the Agency, of
products containing dicofol, pursuant to section 6(f)(1) of the Federal
Insecticide, Fungicide, and Rodenticide Act (FIFRA), as amended. This
cancellation order follows a June 22, 2011 Federal Register Notice of
Receipt of Requests from the registrants listed in Table 3 of Unit II
to voluntarily cancel these product registrations. These are the last
products containing this pesticide registered for use in the United
States. In the June 22, 2011 notice, EPA indicated that it would issue
an order implementing the cancellations, unless the Agency received
substantive comments within the 30 day comment period that would merit
its further review of these requests, or unless the registrants
withdrew their requests. The Agency did not receive any comments on the
notice. Further, the registrants did not withdraw their requests.
Accordingly, EPA hereby issues in this notice a cancellation order
granting the requested cancellations. Any distribution, sale, or use of
the products subject to this cancellation order is permitted only in
accordance with the terms of this order. 11P-1531

DATES: The cancellation of the technical dicofol product is effective
December 14, 2011. The cancellations of the end use registrations are
effective October 31, 2013.

FOR FURTHER INFORMATION CONTACT: Susan M. Bartow, Pesticide Re-
evaluation Division (7508P), Office of Pesticide Programs,
Environmental Protection Agency, 1200 Pennsylvania Ave. NW.,
Washington, DC 20460-0001; telephone number:<PHONE_NUMBER>; email
address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    This action is directed to the public in general, and may be of
interest to a wide range of stakeholders including environmental, human
health, and agricultural advocates; the chemical industry; pesticide
users; and members of the public interested in the sale, distribution,
or use of pesticides. Since others also may be interested, the Agency
has not attempted to describe all the specific entities that may be
affected by this action. If you have any questions regarding the
applicability of this action to a particular entity, consult the person
listed under FOR FURTHER INFORMATION CONTACT.

B. How can I get copies of this document and other related information?

    EPA has established a docket for this action under docket
identification (ID) number EPA-HQ-OPP-2005-0220. Publicly available
docket materials are available either in the electronic docket at
http://www.regulations.gov, or, if only

available in hard copy, at the Office of Pesticide Programs (OPP)
Regulatory Public Docket in Rm. S-4400, One Potomac Yard (South Bldg.),
2777 S. Crystal Dr. Arlington, VA. The hours of operation of this
Docket Facility are from 8:30 a.m. to 4 p.m., Monday through Friday,
excluding legal holidays. The Docket Facility telephone number is (703)
305-5805.

II. What action is the agency taking?

    This notice announces the cancellation of dicofol products, as
requested by registrants, pursuant to section 6(f) of FIFRA. These
registrations are listed in sequence by registration number in Table 1
and Table 2 of this unit.

             Table 1--Dicofol Technical Product Cancellation
------------------------------------------------------------------------
           EPA registration No.                     Product name
------------------------------------------------------------------------
11603-26..................................  Mitigan (Dicofol) Technical.
------------------------------------------------------------------------

             Table 2--Dicofol End Use Product Cancellations
------------------------------------------------------------------------
           EPA registration No.                     Product name
------------------------------------------------------------------------
66222-21..................................  MANA Dicofol 4E.
66222-56..................................  Dicofol 4E.
66222-95..................................  Dicofol 50WSB.
------------------------------------------------------------------------

    Table 3 of this unit includes the names and addresses of record for
all registrants of the products listed in Tables 1 and 2 of this unit,
in sequence by EPA company number.

               Table 3--Registrants of Cancelled Products
------------------------------------------------------------------------
              EPA company No.                 Company name and  address
------------------------------------------------------------------------
11603.....................................  Agan Chemical Manufacturing
                                             Ltd, 4515 Falls of Neuse
                                             Rd. Suite 300, Raleigh, NC
                                             27609.
66222.....................................  Makhteshim Agan of North
                                             America, Inc, 4515 Falls of
                                             Neuse Rd. Suite 300,
                                             Raleigh, NC 27609.
------------------------------------------------------------------------

III. Summary of Public Comments Received and Agency Response to
Comments

    During the public comment period provided, EPA received no comments
in response to the June 22, 2011 Federal Register notice announcing the
Agency's receipt of the requests for voluntary cancellations of
products listed in Tables 1 and 2 of Unit II.

 IV. Cancellation Order

    Pursuant to FIFRA section 6(f), EPA hereby approves the requested
cancellations and amendments to terminate the uses of dicofol
registrations identified in Tables 1 and 2 of Unit II. Accordingly, the
cancellation of the technical dicofol product is effective immediately.
The cancellation of the end use registrations is effective October 31,
2013. Any distribution, sale, or use of existing stocks of the products
identified in Tables 1 and 2 of Unit II in a manner inconsistent with
any of the provisions for disposition of existing stocks set forth in
Unit VI will be a violation of FIFRA.

V. What is the agency's authority for taking this action?

    Section 6(f)(1) of FIFRA provides that a registrant of a pesticide
product may at any time request that any of its pesticide registrations
be canceled or amended to terminate one or more uses. FIFRA further
provides that, before acting on the request, EPA must publish a notice
of receipt of any such request in the Federal Register. Thereafter,
following the public comment period, the EPA Administrator may approve
such a request. The notice of receipt for this action was published for
comment on June 22, 2011 (76 FR 36535) (FRL-8875-7). The comment period
closed on July 22, 2011.

VI. Provisions for Disposition of Existing Stocks

    Existing stocks are those stocks of registered pesticide products
which are currently in the United States and which were packaged,
labeled, and released for shipment prior to the effective date of the
action. The existing stocks provision for the products subject to this
order is as follows:
    a. Sale, distribution and use of the technical dicofol is
prohibited, except: Registrants of dicofol end-use products shall be
allowed to reformulate existing stocks of dicofol technical into
products identified in Table 2 of Unit II, until October 31, 2013, or
for products intended for export consistent with the requirements of
FIFRA section 17 or for purposes of proper disposal.
    b. Sale and distribution by registrants of end use products after
October 31, 2013 is prohibited except for export consistent with the
requirements of FIFRA section 17 or for purposes of proper disposal.
    c. Sale and distribution of end use products by persons other than
registrants is permitted until December 31, 2013. Thereafter, sale and
distribution of end use products by persons other than registrants is
prohibited except for export consistent with the requirements of FIFRA
section 17 or for purposes of proper disposal.
    d. Use of existing stocks of any end-use product consistent with
the terms of the previously approved labeling on, or accompanied by,
the deleted products identified shall be allowed until October 31,
2016, and thereafter, only for the purposes of proper disposal.

List of Subjects

    Environmental protection, Pesticides and pests.

    Dated: December 6, 2011.
Richard P. Keigwin, Jr.,
Director, Pesticide Re-evaluation Division, Office of Pesticide
Programs.
[FR Doc. 2011-31987 Filed 12-13-11; 8:45 am]
BILLING CODE 6560-50-P


[Federal Register: August 21, 2009 (Volume 74, Number 161)]
[Notices]
[Page 42361]
[DOCID:fr21au09-119]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

RTCA Program Management Committee

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of RTCA Program Management Committee meeting.

-----------------------------------------------------------------------

SUMMARY: The FAA is issuing this notice to advise the public of a
meeting of the RTCA Program Management Committee.

DATES: The meeting will be held September 9, 2009 starting at 8:30 a.m.
to 1:30 p.m.

ADDRESSES: The meeting will be held at RTCA, Inc., 1828 L Street, NW.,
Suite 805, Washington, DC 20036.

FOR FURTHER INFORMATION CONTACT: RTCA Secretariat, 1828 L Street, NW.,
Suite 850, Washington, DC 20036; telephone<PHONE_NUMBER>; fax (202)
833-9434; Web site http://www.rtca.org.

SUPPLEMENTARY INFORMATION: Pursuant to section 10(a)(2) of the Federal
Advisory Committee Act (Pub. L. 92-463, 5 U.S.C., Appendix 2), notice
is hereby given for a NextGen Mid-Term Implementation Task Force
meeting. The agenda will include:
     Opening Plenary (Welcome and Introductions).
     Review/Approve Summary of July 1, 2009 PMC meeting, RTCA
Paper No. 163-09/PMC-738.
     Publication Consideration/Approval.
     Final Draft, New Document, Safety, Performance and
Interoperability Requirements Document for Enhanced Air Traffic
Services in Radar-Controlled Areas using ADS-B Surveillance (ADS-B-
RAD), RTCA Paper No. 170-09/PMC-743, prepared by SC-186.
     Integration and Coordination Committee (ICC)--Report.
     Action Item Review.
     SC-218--Future ADS-B/TCAS Relationships--Discussion--
Status.
     SC-203--Unmanned Aircraft Systems (UAS)--Discussion--
Status.
     Discussion.
     SC-214--Standards for Air Traffic Data Communications
Services--Discussion--DO-258A, Interoperability Requirements for ATS
Applications Using ARINC 622 Data Communications.
     Special Committee Chairman's Reports.
     Other Business.
     Closing Plenary (Other Business, Document Production, Date
and Place of Next Meeting, Adjourn).
    Attendance is open to the interested public but limited to space
availability. With the approval of the chairman, members of the public
may present oral statements at the meeting. Persons wishing to present
statements or obtain information should contact the person listed in
the FOR FURTHER INFORMATION CONTACT section.
    Members of the public may present a written statement to the
committee at any time.

    Issued in Washington, DC, on August 13, 2009.
Francisco Estrada C.,
RTCA Advisory Committee.
[FR Doc. E9-20125 Filed 8-20-09; 8:45 am]

BILLING CODE 4910-13-P


[Federal Register Volume 78, Number 122 (Tuesday, June 25, 2013)]
[Notices]
[Pages 38055-38057]
[FR Doc No: 2013-15097]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-0012]

Building Research Capacity in Global Tobacco Product Regulation
Program (U18)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of grant funds for the support of the Center for Tobacco
Product's (CTP's) Building Research Capacity in Global Tobacco Product
Regulation Program. FDA intends to accept and consider a single source
application for award to the World Health Organization (WHO) to
identify, support, develop, conduct, and coordinate research efforts
relating to tobacco control laws and rules in foreign countries that
will directly inform and support FDA's exercise of its authority to
regulate the manufacture, distribution, marketing, and sale of tobacco
products in the United States. The Building Research Capacity in Global
Tobacco Product Regulation Program seeks to advance and expand research
in support of tobacco product regulation, in order to reduce the
morbidity and mortality associated with tobacco use both within the
United States and internationally. The program will advance FDA's and
CTP's mission by utilizing WHO Member States' expertise and extensive
international contacts in global tobacco control, as well as WHO's own
programmatic expertise, to inform and support adequate manufacture,
distribution, and market regulations of tobacco products for the
protection of public health in the United States.

DATES: Important dates are as follows:
    1. The application due date is July 31, 2013.
    2. The anticipated start date is September 2013.
    3. The opening date is July 1, 2013.
    4. The expiration date is August 1, 2013.

ADDRESSES: Submit electronic applications to: http://www.grants.gov.
For more information, see section III of the SUPPLEMENTARY INFORMATION
section of this notice.

FOR FURTHER INFORMATION CONTACT: Caitlin Addorisio, Center for Tobacco
Products, Food and Drug Administration, 9200 Corporate Blvd.,
Rockville, MD 20850,<PHONE_NUMBER>; or Lisa Ko, Office of Acquisition
and Grants Services, Food and Drug Administration, 5630 Fishers Lane,
Rockville, MD 20857,<PHONE_NUMBER>.
    For more information on this funding opportunity announcement (FOA)
and to obtain detailed requirements, please refer to the full FOA
located at http://www.grants.gov. Search by Funding Opportunity Number:
RFA-FD-13-032.

SUPPLEMENTARY INFORMATION:

I. Funding Opportunity Description

    RFA-FD-13-032.
    93.103.

A. Background

1. Authority
    The Building Research Capacity in Global Tobacco Product Regulation
Program is authorized by 42 U.S.C. 241 of the Public Health Service Act
and the Family Smoking Prevention and Tobacco Control Act (Pub. L. 111-
31).
2. Program Background
    Tobacco use is the foremost preventable cause of premature death in
America. It causes over 443,000 deaths in the United States each year,
and another 8.6 million smokers have at least one serious illness due
to smoking. A compelling body of evidence illustrates that tobacco
products are inherently dangerous and cause cancer, heart disease, and
other serious adverse health effects.
    On June 22, 2009, President Obama signed the Tobacco Control Act,
giving FDA regulatory authority to regulate the manufacturing,
labeling, sale, distribution, advertising, and promotion of tobacco
products.
    Some key FDA activities authorized or required by the Tobacco
Control Act include:
     Mandating larger, more varied, and more prominent warning
labels on cigarette and smokeless tobacco products (Title II of the
Tobacco Control Act).
     Restricting tobacco product sales, advertising, and
promotion (section 906(d) of the Federal Food, Drug, and Cosmetic Act
(FD&C Act) (21 U.S.C 387f(d)); section 102 of the Tobacco Control
Act)).
     Establishing product standards to regulate the contents,
design, components, emissions, and other characteristics of tobacco
products

(section 907 of the FD&C Act) (21 U.S.C 387g).
     Prohibiting explicit and implicit claims of modified risk
or modified exposure (including ``light,'' ``low,'' or ``mild'' and
similar descriptors), without an FDA order that the modified risk
product may be marketed (section 911 of the FD&C Act) (21 U.S.C. 387k).
     In general (with certain narrow exceptions), limiting the
introduction of new tobacco products to those for which FDA determines
that the marketing of the product would be ``appropriate for the
protection of public health'' (sections 905, 910 of the FD&C Act) (21
U.S.C. 387e, 387j).
     Collecting data on certain tobacco product constituents,
ingredients, and additives and establishing a list of harmful and
potentially harmful constituents in tobacco products, including smoke
constituents, by brand and subbrand (sections 904, 915 of the FD&C Act)
(21 U.S.C. 387d, 387o).
    Please visit http://www.fda.gov/TobaccoProducts/default.htm for
more information on the Tobacco Control Act and related regulations,
guidance, and other educational information.
    To implement the new law, Congress directed the creation of CTP at
FDA. CTP oversees the implementation of the Tobacco Control Act. CTP's
mission is to protect Americans from tobacco-related death and disease
by regulating the manufacture, distribution, and marketing of tobacco
products and by educating the public, especially young people, about
tobacco products and the dangers their use poses to themselves and
others.
    Protecting the public health requires multidimensional programs
that address both immediate threats as well as their systemic causes.
Using this public health approach, CTP can successfully deter youth
from ever using tobacco products while encouraging current consumers to
quit. CTP will communicate broadly and effectively about the Agency's
new responsibilities for tobacco product regulation and the dangers
tobacco use poses to young people and adults. CTP will use its unique
authorities to develop strategies to decrease the harms associated with
the use of tobacco products. CTP will expand its research program and,
with it, its proven commitment to regulatory science.
    CTP's strategic public health goals include:
     Decreasing initiation of tobacco product use, especially
among youth,
     Decreasing the harms of tobacco product use, and
     Encouraging tobacco use cessation.
3. Overarching Program Goal
    The goal of the Building Research Capacity in Global Tobacco
Product Regulation Program is to advance and expand research in support
of tobacco product regulation, in order to reduce the morbidity and
mortality associated with tobacco use both within the United States and
internationally.
    WHO, in particular WHO's Tobacco Free Initiative, will conduct and
coordinate data collection, expert insights and analysis, and other
research to support tobacco product regulation activities. WHO's
activities provide a universal public health benefit by identifying and
analyzing tobacco regulatory challenges, collating science-based tools
to combat such challenges, and enhancing regulatory capabilities of
governments to implement successful tobacco product regulation and
decrease the global use of tobacco products. The activities provide a
significant domestic benefit, as the scientific, policy, and legal
research gathered will contribute to FDA's own tobacco product
regulation activities aimed at decreasing domestic tobacco-related
death and disease, and the American public will gain new information
about tobacco products and the dangers their use poses.
    As highlighted previously, CTP continues to take steps to implement
the Tobacco Control Act. It is beneficial for FDA to learn from the
successes and failures of other international regulatory agencies and
consider the vast research available globally to inform FDA's
decisions. As CTP considers its mandate to place restrictions on the
sale and distribution of tobacco products, implement tobacco product
standards, review applications for new tobacco products, and consider
applications for modified risk products, among other activities, it is
important to consider global trends, scientific literature, and the
support/scientific information/research or evaluation opportunities in
other countries' relevant tobacco experience. The Building Research
Capacity in Global Tobacco Product Regulation Program will help support
a global network of tobacco product regulators that will enable robust
information sharing and health research collection globally, thereby
catalyzing the use of best practices, and complementing CTP's
regulatory efforts.

B. Research Objectives

1. Program Purpose
    The purpose of the Building Research Capacity in Global Tobacco
Product Regulation Program is to identify, support, develop, conduct,
and coordinate research efforts relating to tobacco control laws and
rules in foreign countries that will directly inform and support FDA's
exercise of its authority to regulate the manufacture, distribution,
marketing, and sale of tobacco products in the United States.
    The program will advance CTP's mission by utilizing the WHO's
Member States' expertise and extensive international contacts in global
tobacco control, as well as WHO's own programmatic expertise, to inform
and support adequate manufacture, distribution, and market regulations
of tobacco products for the protection of public health in the United
States.
2. Program Priorities
    The Program's grant funds will support WHO in expanding the
research foundation for tobacco product regulation, in an effort to
support FDA's implementation of the Tobacco Control Act. It is expected
that this effort may also support foreign governments' development of
tobacco control policies and regulations. A strong application will
seek to increase comprehensive data collection, expert insight and
analysis, and other research related to scientific, legal, and policy
information that can contribute to successful domestic regulation and
policies that will protect Americans from tobacco-related death and
disease and promote public understanding of tobacco risk.
    The application must include the following activities: (1) Propose
a program plan, relying on WHO's long history of coordinating
international collaborative projects in support of tobacco control
development and its established international contacts, that supports
FDA approaches to reducing tobacco use, harm, and addiction; (2)
identify, support, develop, conduct, and coordinate multilateral
research efforts in the areas of science, law, policy, and public
health communications/education that advance FDA's regulation of the
manufacturing, marketing, and distribution of tobacco products as found
in the Tobacco Control Act; (3) plan, build, adapt, or expand data
collection/information sharing mechanisms, management, and reporting
protocols necessary to facilitate Program information exchanges,
analysis, and other research; and (4) evaluate program activities,
processes, and outcomes, including summation evaluation, to document
and disseminate results and outcomes.
    The applicant must propose science-based activities that advance
the international tobacco product regulation research foundation in
order to reduce tobacco-related death and disease both

in the United States and around the world. The applicant should track
both short-term and long-term goals, and demonstrate how the proposed
activities are related to CTP's regulation of tobacco products under
the Tobacco Control Act.
    By way of example, project activities could:
     In the first year, draft a long-term strategy for
increasing WHO's capacity to facilitate global tobacco-related
research;
     Create global data information systems to support the
program research goals and allow for efficient and timely information
sharing with FDA and other partners;
     Continue to coordinate and mobilize an international
tobacco regulators' network, via conferences, workshops,
teleconferences, and other regular engagements, for the purpose of
sharing global tobacco regulation experience and expertise; and
     Analyze tobacco-related research and produce technical
papers on various issues of relevance to tobacco product regulation,
e.g., illicit trade in tobacco products, tobacco control and
intellectual property rights, tobacco control and international trade,
nicotine addiction, and other topics.
    The applicant must be familiar with the specific provisions of the
Tobacco Control Act and the regulatory activities of FDA. In addition
to demonstrating how the proposed project is related to CTP's
regulation of tobacco products under the Tobacco Control Act, the
applicant must demonstrate how it will advance the public health goals
that underlie these FDA activities. Please visit http://www.fda.gov/TobaccoProducts/default.htm for more information on the Tobacco Control
Act and related regulations, guidance, and other educational
information.

C. Eligibility Information

    The following organization is eligible to apply: WHO.
    As FDA seeks to proactively work with other countries and identify
research and evaluation opportunities that will impact FDA's ability to
successfully implement the Tobacco Control Act, further collaboration
with WHO is anticipated. With the financial support from FDA, WHO is
uniquely qualified to undertake these activities, given its mandate,
wide access to data, participation of member states, and access to
worldwide regulatory expertise.
Specific Evidence To Justify Single Eligibility
     Example databases already in place:
    [cir] WHO Framework Convention on Tobacco Control Health Warnings
Database (http://www.who.int/tobacco/healthwarningsdatabase/en/index.html).
    [cir] Tobacco Industry Monitoring Database.
     Examples of Global Tobacco Research Reports/White Papers:
    [cir] WHO report on the global tobacco epidemic, 2001, 2009, 2008.
    [cir] Developing Legislation for Tobacco Control.
    [cir] WHO Study Group on Tobacco Product Regulation Report on the
Scientific Basis of Tobacco Product Regulation.
    [cir] Confronting the tobacco epidemic in a new era of trade and
investment liberalization.
    [cir] See more examples at: http://www.who.int/tobacco/publications/prod_regulation/en/index.html.
     Examples of Global Tobacco Regulator Workshops and
Meetings/Network of Scientists:
    [cir] Tobacco Product Regulation (TobReg): http://www.who.int/tobacco/industry/product_regulation/tobreg/en/index.html.
    [cir] Tobacco Laboratory Network (TobLabNet): http://www.who.int/tobacco/industry/product_regulation/toblabnet/en/index.html.
    [cir] Experience coordinating and conducting regular scientific
meetings: http://www.who.int/tobacco/industry/product_regulation/toblabnet/meetings/en/index.html.
    [cir] 2011 International Tobacco Regulators Conference that was
cosponsored by WHO and FDA: http://www.who.int/tobacco/industry/product_regulation/forum/conference2012.pdf.

II. Award Information/Funds Available

A. Award Amount

    FDA/CTP anticipates providing in fiscal year (FY) 2013 up to $1
million (total costs including indirect costs for one award subject to
availability of funds) in support of this project. FDA/CTP anticipates
the possibility of four additional years of support up to $4 million of
funding contingent upon successful performance and the availability of
funding. Program funds may not be used for any purpose other than those
directly tied to the regulation of tobacco products under the Tobacco
Control Act.
     FY Funds: 2013.
     Estimated Current FY Funding: $1 million.
     Maximum Size Award in Current Fiscal Year: $1 million.
     Estimated Number of Awards: 1.
     Estimated Future Year Funding: FY 2014 ($1 million), FY
2015 ($1 million), FY 2016 ($1 million), and FY 2017 ($1 million).
     Maximum Size Award in Future Years: FY 2014 ($1 million),
FY 2015 ($1 million), FY 2016 ($1 million), and FY 2017 ($1 million).
     Maximum Project Period: 5 Years.

B. Length of Support

    The length of support will depend on the nature of the project. The
budget period in current and future funding years will be as follows:
FY 2013 (12 months), FY 2014 (12 months), FY 2015 (12 months), FY 2016
(12 months), and FY 2017 (12 months).

III. Electronic Application, Registration, and Submission

    Only electronic applications will be accepted. To submit an
electronic application in response to this FOA, applicants should first
review the full announcement located at http://www.grants.gov. Search
by Funding Opportunity Number: RFA-FD-13-032. (FDA has verified the Web
site addresses throughout this document, but FDA is not responsible for
any subsequent changes to the Web sites after this document publishes
in the Federal Register.) For all electronically submitted
applications, the following steps are required.
    Step 1: Obtain a Dun and Bradstreet (DUNS) Number.
    Step 2: Register With System for Award Management (SAM).
    Step 3: Obtain Username & Password.
    Step 4: Authorized Organization Representative (AOR) Authorization.
    Step 5: Track AOR Status.
    Step 6: Register With Electronic Research Administration (eRA)
Commons.
    Steps 1 through 5, in detail, can be found at http://www07.grants.gov/applicants/organization_registration.jsp. Step 6, in
detail, can be found at https://commons.era.nih.gov/commons/registration/registrationInstructions.jsp. After you have followed
these steps, submit electronic applications to: http://www.grants.gov.

    Dated: June 19, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-15097 Filed 6-24-13; 8:45 am]
BILLING CODE 4160-01-P


Placeholder: confidential business information item

INEOS Fluor Presentation on 10-14-08

For more information please contact Ross Brennan by phone at
202-343-9226 or by email at   HYPERLINK<EMAIL_ADDRESS><EMAIL_ADDRESS>


[Federal Register Volume 81, Number 167 (Monday, August 29, 2016)]
[Notices]
[Pages 59207-59208]
[FR Doc No: 2016-20630]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER16-2459-000]

Emera Energy Services Subsidiary No. 15 LLC; Supplemental Notice
That Initial Market-Based Rate Filing Includes Request for Blanket
Section 204 Authorization

    This is a supplemental notice in the above-referenced proceeding of
Emera Energy Services Subsidiary No. 15 LLC`s application for market-
based rate authority, with an accompanying rate tariff, noting that
such application includes a request for blanket authorization, under 18
CFR part 34, of future issuances of securities and assumptions of
liability.
    Any person desiring to intervene or to protest should file with the
Federal Energy Regulatory Commission, 888 First Street NE., Washington,
DC 20426, in accordance with Rules 211 and 214 of the Commission's
Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Anyone
filing a motion to intervene or protest must serve a copy of that
document on the Applicant.
    Notice is hereby given that the deadline for filing protests with
regard to the applicant's request for blanket authorization, under 18
CFR part 34, of future issuances of securities and assumptions of
liability, is September 12, 2016.
    The Commission encourages electronic submission of protests and

interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with Internet
access who will eFile a document and/or be listed as a contact for an
intervenor must create and validate an eRegistration account using the
eRegistration link. Select the eFiling link to log on and submit the
intervention or protests.
    Persons unable to file electronically should submit an original and
5 copies of the intervention or protest to the Federal Energy
Regulatory Commission, 888 First Street NE., Washington, DC 20426.
    The filings in the above-referenced proceeding are accessible in
the Commission's eLibrary system by clicking on the appropriate link in
the above list. They are also available for electronic review in the
Commission's Public Reference Room in Washington, DC. There is an
eSubscription link on the Web site that enables subscribers to receive
email notification when a document is added to a subscribed docket(s).
For assistance with any FERC Online service, please email
<EMAIL_ADDRESS>or call<PHONE_NUMBER> (toll free). For
TTY, call<PHONE_NUMBER>.

    Dated: August 23, 2016.
Kimberly D. Bose,
Secretary.
[FR Doc. 2016-20630 Filed 8-26-16; 8:45 am]
 BILLING CODE 6717-01-P


<!DOCTYPE HTML PUBLIC "-//-//W3C//DTD HTML 3.2//EN">

<META name="generator" content="Document">
<META name="creation-date" content="05/04/2010 12:48:24 ">
<TITLE>Document</TITLE>

17142
Federal Register/Vol. 75, No. 64/Monday, April 5, 2010/Notices
Respondents: Business or other for–
profit, not–for–profit institutions, and
state, local or tribal government.
Number of Respondents and
Responses: 3,788 respondents; 3,788
responses.
Estimated Time per Response: .25
minutes.
Frequency of Response: One time
reporting requirement.
Obligation to Respond: Required to
obtain or retain benefits. Statutory
authority for this information collection
is contained in 47 U.S.C. 308(b).
Total Annual Burden: 947 hours.
Total Annual Cost: N/A.
Privacy Act Impact Assessment: N/A.
Nature and Extent of Confidentiality:
No questions of a confidential nature are
asked.
Needs and Uses: The Commission
will submit this expiring information
collection to the Office of Management
and Budget during this comment period
under delegated authority. The
Commission inadvertently published a
regular notice rather than a delegated
notice announcing submission of this
information collection at the end of the
60 day comment period which was
March 29, 2010 (75 FR 4077, January 26,
2010). Therefore, the Commission is
required to publish a 30 day notice
following a regular notice. The
Commission is reporting no change to
the reporting requirement. However,
there is a 1,436 hour reduction
adjustment to the total annual burden
hours since the last submission to the
OMB in 2007. This reduction is due to
5,743 fewer respondents.
This rule section requires that affected
applicants to submit a list of any radio
facilities they hold within 40 miles of
the base station transmitter site being
applied for. This information is used to
determine if an applicant’s proposed
system is necessary in light of
communications facilities it already
owns. Such a determination helps the
Commission to equitably distribute
limited spectrum and prevents spectrum
warehousing. The information is
collected only once – upon initial
license application.
Federal Communications Commission.
Marlene H. Dortch,
Secretary,
Office of the Secretary,
Office of Managing Director.
[FR Doc. 2010–7557 Filed 4–2–10; 8:45 am]
BILLING CODE 6712–01–S
FEDERAL RESERVE SYSTEM
Change in Bank Control Notices;
Acquisition of Shares of Bank or Bank
Holding Companies
The notificants listed below have
applied under the Change in Bank
Control Act (12 U.S.C. 1817(j)) and
§225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire a bank or bank
holding company. The factors that are
considered in acting on the notices are
set forth in paragraph 7 of the Act (12
U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the office of the Board of Governors.
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than April 19,
2010.
A. Federal Reserve Bank of Richmond
(A. Linwood Gill, III, Vice President)
701 East Byrd Street, Richmond,
Virginia 23261-4528:
1. David Muldrow Beasley, Society
Hill, South Carolina, individually and
as a member of a group acting in concert
including Henry Wesley Beasley,
Richard Lewis Beasley, both of
Florence, South Carolina, and Richard
Lee Beasley, Society Hill, South
Carolina, to retain control of First
Carolina Bancshares Corporation,
Darlington, South Carolina, and thereby
indirectly retain control of Carolina
Bank and Trust Company, Lamar, South
Carolina.
Board of Governors of the Federal Reserve
System, March 31, 2010.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2010–7613 Filed 4–2–10; 8:45 am]
BILLING CODE 6210–01–S
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR Part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than April 28, 2010.
A. Federal Reserve Bank of New York
(Anne MacEwen, Bank Applications
Officer) 33 Liberty Street, New York,
New York 10045-0001:
1. The Goldman Sachs Group, Inc.,
New York, New York, to acquire up to
24.9 percent of SKBHC Holdings LLC,
Corona del Mar, California, which is
applying to become a bank holding
company, and thereby indirectly acquire
Starbuck Bancshares, Inc. and The First
National Bank of Starbuck, both of
Starbuck, Minnesota.
Board of Governors of the Federal Reserve
System, March 31, 2010.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2010–7614 Filed 4–2–10; 8:45 am]
BILLING CODE 6210–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA–2009–E–0202 and FDA–
2009–E–0204]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; LUSEDRA
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug
Administration (FDA) has determined
the regulatory review period for
VerDate Nov<24>2008
16:35 Apr 02, 2010
Jkt 220001
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
E:\FR\FM\05APN1.SGM
05APN1

17143
Federal Register/Vol. 75, No. 64/Monday, April 5, 2010/Notices
LUSEDRA and is publishing this notice
of that determination as required by
law. FDA has made the determination
because of the submission of
applications to the Director of Patents
and Trademarks, Department of
Commerce, for the extension of a patent
which claims that human drug product.
ADDRESSES:
Submit written comments
and petitions to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to http://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 51,
rm. 6222, Silver Spring, MD 20993–
0002, 301–796–3602.
SUPPLEMENTARY INFORMATION:
The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98–
417) and the Generic Animal Drug and
Patent Term Restoration Act (Public
Law 100–670) generally provide that a
patent may be extended for a period of
up to 5 years so long as the patented
item (human drug product, animal drug
product, medical device, food additive,
or color additive) was subject to
regulatory review by FDA before the
item was marketed. Under these acts, a
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
effective and runs until the approval
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
permission to market the drug product.
Although only a portion of a regulatory
review period may count toward the
actual amount of extension that the
Director of Patents and Trademarks may
award (for example, half the testing
phase must be subtracted as well as any
time that may have occurred before the
patent was issued), FDA’s determination
of the length of a regulatory review
period for a human drug product will
include all of the testing phase and
approval phase as specified in 35 U.S.C.
156(g)(1)(B).
FDA recently approved for marketing
the human drug product LUSEDRA
(fospropofol disodium). LUSEDRA is a
sedative-hypnotic agent indicated for
monitored anesthesia care sedation in
adult patients undergoing diagnostic or
therapeutic procedures. Subsequent to
this approval, the Patent and Trademark
Office received patent term restoration
applications for LUSEDRA (U.S. Patent
Nos. 6,204,257 and 6,872,838) from
University of Kansas, and the Patent and
Trademark Office requested FDA’s
assistance in determining the patents’
eligibility for patent term restoration. In
a letter dated September 29, 2009, FDA
advised the Patent and Trademark
Office that this human drug product had
undergone a regulatory review period
and that the approval of LUSEDRA
represented the first permitted
commercial marketing or use of the
product. Thereafter, the Patent and
Trademark Office requested that FDA
determine the product’s regulatory
review period.
FDA has determined that the
applicable regulatory review period for
LUSEDRA is 2,405 days. Of this time,
1,962 days occurred during the testing
phase of the regulatory review period,
while 443 days occurred during the
approval phase. These periods of time
were derived from the following dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C.
355(i)) became effective: May 15, 2002.
FDA has verified the applicant’s claim
that the date the investigational new
drug application became effective was
on May 15, 2002.
2. The date the application was
initially submitted with respect to the
human drug product under section
505(b) of the act: September 27, 2007.
FDA has verified the applicant’s claim
that the new drug application (NDA)
22–244 was submitted on September 27,
2007.
3. The date the application was
approved: December 12, 2008. FDA has
verified the applicant’s claim that NDA
22–244 was approved on December 12,
2008.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the U.S. Patent and
Trademark Office applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its applications for patent extension,
this applicant seeks 1,424 days of patent
term extension for patent no. 6,204,257
and 899 days of patent term extension
for patent no. 6,872,838.
Anyone with knowledge that any of
the dates as published are incorrect may
submit to the Division of Dockets
Management (see
ADDRESSES
) written or
electronic comments and ask for a
redetermination by June 4, 2010.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
October 4, 2010. To meet its burden, the
petition must contain sufficient facts to
merit an FDA investigation. (See H.
Rept. 857, part 1, 98th Cong., 2d sess.,
pp. 41–42, 1984.) Petitions should be in
the format specified in 21 CFR 10.30.
Comments and petitions should be
submitted to the Division of Dockets
Management. Three copies of any
mailed information are to be submitted,
except that individuals may submit one
copy. Comments are to be identified
with the docket number found in
brackets in the heading of this
document. Comments and petitions may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Dated: March 22, 2010.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug
Evaluation and Research.
[FR Doc. 2010–7516 Filed 4–2–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–D–0495]
Draft Guidance for Industry and Food
and Drug Administration Staff; Medical
Devices; Neurological and Physical
Medicine Device Guidance Documents;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug
Administration (FDA) is announcing the
availability of draft special controls
guidance documents for 11 neurological
and physical medicine devices. FDA has
developed a draft special controls
guidance document for each of the 11
devices. These draft guidance
documents describe a means by which
these devices may comply with the
requirement of special controls for class
II devices. Elsewhere in this issue of the
Federal Register, FDA is publishing a
proposed rule that would designate
special controls for each of these
devices and would exempt six of them
from the premarket notification
requirements of the Federal Food, Drug,
and Cosmetic Act (the act). These draft
guidance documents are not final nor
are they in effect at this time.
DATES:
Although you can comment on
any guidance documents at any time
VerDate Nov<24>2008
16:35 Apr 02, 2010
Jkt 220001
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
E:\FR\FM\05APN1.SGM
05APN1


[Federal Register Volume 80, Number 23 (Wednesday, February 4, 2015)]
[Notices]
[Pages 6145-6148]
[FR Doc No: 2015-02104]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-74169; File No. SR-CBOE-2015-011]

Self-Regulatory Organizations; Chicago Board Options Exchange,
Incorporated; Notice of Filing of a Proposed Rule Change To Amend
Exchange Rules Related to Order Tickets

January 29, 2015.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(the ``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby given
that on January 23, 2015, Chicago Board Options Exchange, Incorporated
(the ``Exchange'' or ``CBOE'') filed with the Securities and Exchange
Commission (the ``Commission'') the proposed rule change as described
in Items I and II below, which Items have been prepared by the
Exchange. The Commission is publishing this notice to solicit comments
on the proposed rule change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to amend its rules related to order tickets.
The text of

the proposed rule change is provided below.
    (additions are in italics; deletions are [bracketed])
* * * * *

Chicago Board Options Exchange, Incorporated Rules

* * * * *

Rule 6.53. Certain Types of Orders Defined

* * * * *
    . . . Interpretations and Policies:
    .01 No change.
    .02 Complex orders of twelve (12) legs or less (one leg of which
may be for an underlying security or security future, as applicable)
must be entered on a single order ticket at time of systemization. If
permitted by the Exchange (which the Exchange will announce by
Regulatory Circular), complex orders of more than twelve (12) legs (one
leg of which may be for an underlying security or security future, as
applicable) may be split across multiple order tickets, if the Trading
Permit Holder representing the complex order includes twelve (12) legs
on one of the order tickets and identifies for the Exchange the order
tickets that are part of the same complex order (in a form and manner
prescribed by the Exchange).
* * * * *

Rule 24.20. SPX Combo Orders

* * * * *
    . . . Interpretations and Policies:
    .01 An SPX Combo Order for twelve (12) legs or less must be entered
on a single order ticket at time of systemization. If permitted by the
Exchange (which the Exchange will announce by Regulatory Circular), an
SPX Combo Order for more than twelve (12) legs may be represented or
executed as a single SPX Combo Order in accordance with this Rule 24.20
if it is split across multiple order tickets and the Trading Permit
Holder representing the SPX Combo Order includes twelve (12) legs on
one of the order tickets and identifies for the Exchange the order
tickets that are part of the same SPX Combo Order (in a manner and form
prescribed by the Exchange).
* * * * *
    The text of the proposed rule change is also available on the
Exchange's Web site (http://www.cboe.com/AboutCBOE/CBOELegalRegulatoryHome.aspx), at the Exchange's Office of the
Secretary, and at the Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set forth in
sections A, B, and C below, of the most significant aspects of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The Exchange proposes to set forth order ticket requirements
applicable to complex orders in open outcry pursuant to Rule 6.53, as
well as SPX Combo Orders \3\ pursuant to Rule 24.20.
---------------------------------------------------------------------------

    \3\ An ``SPX Combo Order'' consists of an order to purchase or
sell one or more SPX option series and the offsetting number of SPX
combinations defined by the delta, where an ``SPX combination'' is a
purchase (sale) of an SPX call and sale (purchase) of an SPX put
having the same expiration date and strike price and a ``delta'' is
the positive (negative) number of SPX combinations that must be sold
(bought) to establish a market neutral hedge with one or more SPX
option series.
---------------------------------------------------------------------------

Background
    On May 19, 2014, the Exchange submitted a rule change filing (SR-
CBOE-2014-046), which became effective on that date, to amend Rule
24.20, ``SPX Combo Orders''. Rule 24.20, as amended, states: ``For an
order to be eligible for the trading procedures contained in this Rule,
a Trading Permit Holder must apply an indicator to the SPX Combo Order
upon systematization as provided in Rule 6.24.'' \4\ Once the Exchange
implements the combo indicator requirement, TPHs will be required to
apply the combo indicator upon systematization. Orders that include the
combo indicator but do not meet the requirements of an SPX Combo Order
(i.e., orders must be at least three legs and include an SPX
combination \5\) will be rejected. Additionally, the Public Automatic
Routing System (``PAR'') will no longer allow an order to be endorsed
as an SPX Combo Order and reported to OPRA as such.\6\
---------------------------------------------------------------------------

    \4\ Securities Exchange Act Release No. 34-72271 (May 29, 2014),
79 FR 32342 (June 4, 2014) (SR-CBOE-2014-046).
    \5\ SR-CBOE-2014-046 defines an SPX combination as a purchase
(sale) of an SPX call and sale (purchase) of an SPX put having the
same expiration date and strike price.
    \6\ See supra, note 2. Currently, brokers must apply an SPX
Combo Order designation for the purposes of price reporting. This is
accomplished by endorsing a trade via PAR; however the system
changes that allow a combo indicator to be applied upon
systematization will remove the capability to endorse an order as an
SPX Combo Order on PAR, Id.
---------------------------------------------------------------------------

    On August 19, 2014, the Exchange submitted a separate rule change
filing (SR-CBOE-2014-015) to amend, among other things, Rule 24.20 to
include Interpretation and Policy .01.\7\ Proposed Interpretation and
Policy .01 was proposed to require that any complex order in open
outcry, including an SPX Combo Order, for twelve (12) legs or less be
entered on a single order ticket at time of systemization. In addition,
a complex order, including an SPX Combo Order, that contains more than
twelve (12) legs may be represented and executed as a single order, and
for an SPX Combo Order in accordance with Rule 24.20 if it is split
across multiple order tickets and the TPH representing the order
identifies for the Exchange the order tickets that are part of the same
order (in a manner and form prescribed by the Exchange).
---------------------------------------------------------------------------

    \7\ Securities Exchange Act Release No. 34-72975 (September 2,
2014) (``Notice''), 79 FR 53230 (September 8, 2014) (SR-CBOE-2014-
015). SR-CBOE-2014-015 was withdrawn by the Exchange on November 21,
2014, in order to bifurcate the filing into two separate filings.
The first filing is represented by this proposed rule change
regarding the single order ticket requirements. The second filing
will, among other things, include amendments to the complex order
definitions.
---------------------------------------------------------------------------

    Pursuant to rule change filing SR-CBOE-2014-046, the Exchange
issued a Regulatory Circular requiring Trading Permit Holders
(``TPHs'') to begin applying the combo indicator upon systematization
on November 1, 2014.\8\ The implementation date was subsequently
delayed until February 27, 2015 \9\ in order to coincide with the
implementation date of the order ticket requirements in SR-CBOE-2014-
015.\10\
---------------------------------------------------------------------------

    \8\ CBOE Regulatory Circular RG14-125--Implementation of SPX
Combo Order Indicator (August 15, 2014).
    \9\ See CBOE Regulatory Circular RG14-153--Delayed
Implementation of SPX Combo Order Indicator (October 31, 2014).
    \10\ See Securities Exchange Act Release No. 34-73479 (October
31, 2014), 79 FR 66014 (November 6, 2014) (SR-CBOE-2014-083)
(delaying the combo indicator requirement in SR-CBOE-2014-046 in
order to coincide with the order ticket requirements of SR-CBOE-
2014-015).
---------------------------------------------------------------------------

    Pursuant to SR-CBOE-2014-046, a third-party vendor updated the
Exchange provided Floor Broker Workstation (``FBW) to support the combo
indicator. Pursuant to SR-CBOE-2014-015, the Exchange, through a third-
party vendor, developed an enhanced version of FBW to support the

entry of complex orders with up to twelve legs. The enhanced version of
FBW was made available to TPHs for training purposes on January 2,
2015.\11\ The Exchange notes that PULSe, which is an Exchange provided
alternative to FBW, also currently allows up to twelve (12) legs on a
single order ticket and has been updated with the combo indicator.\12\
In addition, the Exchange has been in contact with TPH broker groups
consistently since the filing of SR-CBOE-2014-015 in an effort to
prepare TPH broker groups for the combo indicator and the single order
ticket requirements.\13\
---------------------------------------------------------------------------

    \11\ See RG14-176.
    \12\ The Exchange also notes that TPHs will not be required to
make changes to their own or third-party vendor's order entry and
execution systems. However, to the extent a TPH wants to represent
and execute a multi-part order in open outcry as a complex order,
the order must be entered on a single order ticket and cannot exceed
twelve (12) legs (or, if the Exchange has determined to make it
available, an order for more than twelve (12) legs that is entered
on multiple order tickets, which tickets are linked in a form and
manner prescribed by the Exchange). For example, if a TPH's order
entry and execution system currently only supports the open outcry
processing of a complex order with up to four (4) legs, the system
would not need to be enhanced if the TPH does not intend to
represent and execute complex orders with more than four (4) legs.
If the TPH intends to represent and execute complex orders with more
than four (4) legs (i.e., complex orders with five (5) to twelve
(12) legs), then the TPH may need to enhance its existing system or
utilize another order entry and execution system that supports the
open outcry processing of such orders on a single order ticket.
    \13\ See RG14-125; RG-14-153; and RG14-176. Beyond Regulatory
Circulars, the Exchange has been in contact with TPHs about the
upcoming single order ticket requirements.
---------------------------------------------------------------------------

Proposal
    Currently, Exchange system limitations may prevent a multi-part
order with more than a certain number of legs from being entered on a
single order ticket for representation and execution in open outcry as
a complex order.\14\ As a result, complex orders with more than the
applicable leg limitation that are represented in open outcry must be
split up and entered on multiple order tickets. For consistency in
processing and in order to enhance the Exchange's audit trail, the
Exchange proposes to amend Rules 6.53 to require:
---------------------------------------------------------------------------

    \14\ As noted above, system enhancements currently allow orders
with up to twelve legs to be processed for open outcry.
---------------------------------------------------------------------------

     Complex orders of twelve (12) legs or less (one leg of
which may be for an underlying security or security future, as
applicable) must be entered on a single order ticket at time of
systemization. If permitted by the Exchange (which the Exchange will
announce by Regulatory Circular), complex orders of more than twelve
(12) legs (one leg of which may be for an underlying security or
security future, as applicable) may be split across multiple order
tickets, if the Trading Permit Holder representing the complex order
includes twelve (12) legs on one of the order tickets \15\ and
identifies for the Exchange the order tickets that are part of the same
complex order (in a form and manner prescribed by the Exchange).
---------------------------------------------------------------------------

    \15\ The Exchange recognizes that SR-CBOE-2014-015 indicated
that the Exchange was not imposing requirements on how a complex
order with more than 12 legs should be split across multiple
tickets. See supra note 5, at page 6. However, the Exchange does not
believe TPHs will be adversely affected by the proposed requirement
specifying how an order with more than 12 legs should be split
across multiple tickets because the Exchange believes PULSe, the
enhanced version of FBW, and proprietary systems that TPHs have
designed to comply with the single order ticket requirements of SR-
CBOE-2014-015 are capable of complying with the requirement
specifying how orders with more than 12 legs should be split across
multiple tickets without further programming or configuration.
---------------------------------------------------------------------------

    With respect to the order ticket requirements, the Exchange also
proposes to add to Rule 24.20 (pertaining to SPX Combo Orders)
Interpretation and Policy .01 to require that an SPX Combo Order for
twelve (12) legs or less be entered on a single order ticket at time of
systemization. An SPX Combo Order that contains more than twelve (12)
legs may be represented and executed as a single SPX Combo Order in
accordance with Rule 24.20 if it is split across multiple order tickets
and the TPH representing the SPX Combo Order includes twelve (12) legs
on one of the order tickets \16\ and identifies for the Exchange the
order tickets that are part of the same SPX Combo Order (in a manner
and form prescribed by the Exchange). The Exchange will announce by
Regulatory Circular whether it permits SPX Combo Orders with more than
12 legs and, if so permitted, the form and manner in which the TPH must
link the multiple order tickets. The Exchanges notes that a TPH may
submit an order that does not satisfy these ticket requirements, but
such order may not be represented or executed as a single SPX Combo
Order in accordance with Rule 24.20. The Exchange also notes that Rules
24.20 already specifies an applicable ratio (defined by the delta as
noted above), and it is proposing no changes to the ratio through this
rule filing.
---------------------------------------------------------------------------

    \16\ As noted in the proposed rule text, for an open outcry
complex order and an SPX Combo Order, if an order with more than
twelve legs is split across multiple order tickets, one of the order
tickets must contain twelve legs. For example, a thirteen leg order
cannot have seven legs on one ticket and six legs on another ticket;
rather, one ticket must have twelve legs and the other ticket must
have one leg.
---------------------------------------------------------------------------

    The Exchange will announce the implementation date of the proposed
rule change in a Regulatory Circular to be published within 90 days of
the filing date of this filing. The implementation date of this filing,
if the filing is approved, will be within 180 days of the filing date,
but no earlier than the approval date of the filing.
2. Statutory Basis
    The Exchange believes the proposed rule change is consistent with
the Securities Exchange Act of 1934 (the ``Act'') and the rules and
regulations thereunder applicable to the Exchange and, in particular,
the requirements of Section 6(b) of the Act.\17\ Specifically, the
Exchange believes the proposed rule change is consistent with the
Section 6(b)(5) \18\ requirements that the rules of an exchange be
designed to prevent fraudulent and manipulative acts and practices, to
promote just and equitable principles of trade, to foster cooperation
and coordination with persons engaged in regulating, clearing,
settling, processing information with respect to, and facilitating
transactions in securities, to remove impediments to and perfect the
mechanism of a free and open market and a national market system, and,
in general, to protect investors and the public interest. Additionally,
the Exchange believes the proposed rule change is consistent with the
Section 6(b)(5) \19\ requirement that the rules of an exchange not be
designed to permit unfair discrimination between customers, issuers,
brokers, or dealers.
---------------------------------------------------------------------------

    \17\ 15 U.S.C. 78f(b).
    \18\ 15 U.S.C. 78f(b)(5).
    \19\ Id.
---------------------------------------------------------------------------

    In particular, the Exchange believes enhancing the audit trail with
respect to open outcry complex order processing and SPX Combo Orders
will help to protect investors and the public interest because an
enhanced audit trail promotes transparency and aids in surveillance, as
well as, provides the Exchange the ability to better enforce compliance
by the Exchange's TPHs (and persons associated with its TPHs) with the
Act, the rules and regulations thereunder and the rules of the
Exchange, thereby protecting investors.
    In addition, the Exchange believes the proposed rule change is
consistent with Section 6(b)(1) of the Act,\20\ which provides that the
Exchange be organized and have the capacity to be able to carry out the
purposes of the Act and to enforce compliance by the Exchange's TPHs
(and persons associated with its TPHs) with the Act, the rules and
regulations thereunder and the rules of

the Exchange. Enhancing the audit trail with respect to open outcry
complex order processing will further improve the Exchange's ability to
better enforce compliance by the Exchange's TPHs (and persons
associated with its TPHs) with the Act, the rules and regulations
thereunder and the rules of the Exchange.
---------------------------------------------------------------------------

    \20\ 15 U.S.C. 78f(b)(1).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    CBOE does not believe that the proposed rule change will impose any
burden on competition that is not necessary or appropriate in
furtherance of the purposes of the Act. The Exchange does not believe
that the proposed rule change will impose any burden on intramarket or
intermarket competition because the order ticket requirements will be
applicable to all TPHs executing complex orders in open outcry and SPX
Combo Orders.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    The Exchange neither solicited nor received comments on the
proposal.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Within 45 days of the date of publication of this notice in the
Federal Register or within such longer period up to 90 days (i) as the
Commission may designate if it finds such longer period to be
appropriate and publishes its reasons for so finding or (ii) as to
which the Exchange consents, the Commission will:
    A. By order approve or disapprove such proposed rule change, or
    B. institute proceedings to determine whether the proposed rule
change should be disapproved.
    The Exchange has requested accelerated approval of the proposed
rule change. The Commission is considering granting accelerated
approval of the proposed rule change at the end of a 15-day comment
period.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an email to<EMAIL_ADDRESS>Please include
File Number SR-CBOE-2015-011 on the subject line.

Paper Comments

     Send paper comments in triplicate to Secretary, Securities
and Exchange Commission, 100 F Street NE., Washington, DC 20549-1090.
All submissions should refer to File Number SR-CBOE-2015-011. This file
number should be included on the subject line if email is used. To help
the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml). Copies of the submission, all subsequent amendments, all
written statements with respect to the proposed rule change that are
filed with the Commission, and all written communications relating to
the proposed rule change between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for Web site viewing and
printing in the Commission's Public Reference Room, 100 F Street NE.,
Washington, DC 20549 on official business days between the hours of
10:00 a.m. and 3:00 p.m. Copies of the filing also will be available
for inspection and copying at the principal office of the Exchange. All
comments received will be posted without change; the Commission does
not edit personal identifying information from submissions. You should
submit only information that you wish to make available publicly. All
submissions should refer to File Number SR-CBOE-2015-011 and should be
submitted on or before February 19, 2015.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\21\
---------------------------------------------------------------------------

    \21\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Jill M. Peterson,
Assistant Secretary.
[FR Doc. 2015-02104 Filed 2-3-15; 8:45 am]
BILLING CODE 8011-01-P